SpyGlass Pharma, Inc.
$24.52
▼
-8.1%
2026-04-21 09:23:01
www.spyglasspharma.com
NMS: SGP
Explore SpyGlass Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$833.66 M
Current Price
$24.52
52W High / Low
$32.44 / $20.15
Stock P/E
—
Book Value
$-44.85
Dividend Yield
—
ROCE
-38.64%
ROE
-67.7%
Face Value
—
EPS
$-1.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
1.5
Current Ratio
12.67
Quick Ratio
12.67
Forward P/E
-10.82
Price / Sales
—
Enterprise Value
$792.28 M
EV / EBITDA
-19.4
EV / Revenue
—
Rating
Strong Buy
Target Price
$45
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Septerna, Inc. | $26.86 | — | $1.17 B | — | -15.87% | -12.19% | $32.63 / $5.73 | $8.52 |
| 2. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 3. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 4. | Replimune Group, Inc. | $2.07 | — | $170.93 M | — | -53.14% | -90.88% | $13.24 / $1.5 | $2.64 |
| 5. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 6. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 7. | Humacyte, Inc. | $0.69 | — | $157.68 M | — | -110.35% | 164.78% | $2.93 / $0.55 | $0.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q4 2024 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -13.63 M | -7.75 M |
| Net Profit | -12.56 M | -8.4 M |
| EPS in Rs | -0.38 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -41.45 M | -27.06 M | -14.23 M |
| Net Profit | -39.87 M | -29.16 M | -13.32 M |
| EPS in Rs | -1.19 | -0.87 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 115.87 M | 23.32 M | 41.15 M |
| Total Liabilities | 214.7 M | 83.79 M | 74.13 M |
| Equity | -98.84 M | -60.47 M | -32.99 M |
| Current Assets | 108.77 M | 17.41 M | 40.61 M |
| Current Liabilities | 8.58 M | 7.79 M | 1.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -32.7 M | -22.03 M | -12.28 M |
| Investing CF | -11.79 M | 22.26 M | -20.49 M |
| Financing CF | 124.58 M | 0.18 M | 39.77 M |
| Free CF | -33.49 M | -24.02 M | -12.49 M |
| Capex | -0.79 M | -1.99 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -36.71% | -118.97% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.